Enhertu significantly improves invasive disease-free survival in high-risk HER2-positive early breast cancer patients compared to Kadcyla post-neoadjuvant therapy. DESTINY-Breast05 trial results ...
– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...
-At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy- -These unprecedented results support its ...
Please provide your email address to receive an email when new articles are posted on . Patients with early invasive breast cancer who did not receive axillary surgery had noninferior outcomes as ...
Elderly patients with acute coronary syndrome face trade-offs with an early invasive strategy compared with a more conservative approach, with reduced risks of recurrent events but a heightened ...
– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback